EPA is facing strong criticism from a broad range of stakeholders over its proposal to ease pharmaceutical waste regulations, with state regulators, industry groups and public water treatment authorities all raising concerns that the proposal will be largely ineffective in achieving the agency's stated goals of increasing the proper disposal of pharmaceutical wastes and promoting pharmaceutical take-back programs. Much of the criticism stems from concerns that the agency's proposal will be rendered moot if other federal agencies do not similarly revise their own regulations.
展开▼
